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Rapidly growing mycobacteria (RGM) are respiratory pathogens in patients with cystic fibrosis (CF), but
detection generally requires specialized cultures for acid-fast bacilli (AFB; AFB cultures). We determined that
RGM could be recovered from routine cultures of samples from patients with CF by extending incubation of
the Burkholderia cepacia selective agar (BCSA) from 5 to 14 days. To explore the impact of this modification,
we compared results from routine and AFB cultures of samples from CF patients for 2 years before (4,212
samples by routine culture, 1,810 samples by AFB culture, 670 patients) and 2 years after (4,720 samples by
routine culture, 2,179 samples by AFB culture, 695 patients) the change. Clinical relevance was assessed with
samples from a subgroup of 340 patients followed regularly throughout both periods. Extending incubation of
BCSA enhanced RGM recovery from routine cultures (0.7% before, 2.8% after; P < 0.001); recovery from AFB
cultures was unchanged (5.5% before, 5.7% after). Estimates of RGM detection sensitivity by culture or
patient-based methods ranged from 65 to 75% for routine cultures (nonsignificantly lower than the 80 to
85% for AFB cultures) and were adversely affected by coculture with mold or nonpseudomonal, nonfermenting
Gram-negative rods. In the after period, 16 CF patients met the criteria for RGM infection by routine culture,
including 4 who did not meet the criteria for RGM infection by AFB culture. We conclude that a simple
methodological change enhanced recovery of RGM from routine cultures. The modified culture method could
be utilized to improve screening for RGM in CF patients or as a simpler method to follow patients with known
RGM infection. However, this method should be used cautiously in patients with certain coinfections.
Rapidly growing mycobacteria (RGM) represent a subgroup
of environmental mycobacteria that includes the commonly
recognized pathogen Mycobacterium abscessus as well as other
species, such as M. fortuitum and M. chelonae (1). Accumulat-
ing evidence suggests that RGM are significant respiratory
pathogens within patients with chronic lung diseases such as
cystic fibrosis (CF) (2, 8). A large prospective study showed
that RGM respiratory infection was relatively common in CF
patients (prevalence, 2.3%) (12), and CF patients with chronic
RGM infection have been shown to have greater declines in
lung function over time (3).
Although these data suggest that RGM are significant
pathogens in patients with CF, detection of RGM respiratory
infection poses considerable challenges. While RGM are ca-
pable of growth on many standard culture media, they grow
relatively slowly (they are rapidly growing only relative to the
rate of growth of other mycobacteria) and are typically over-
grown by other common CF pathogens, such as Pseudomonas
aeruginosa, on nonselective agar. As a result, detection of
RGM in respiratory secretions from patients with CF is gen-
erally performed using culture for acid-fast bacilli (AFB; AFB
culture) by techniques that involve a decontamination step to
eliminate Pseudomonas and other competing pathogens (15).
AFB cultures require considerable time and expense and are
generally performed less often and more selectively than rou-
tine culture of respiratory secretions. Indeed, Cystic Fibrosis
Foundation guidelines recommend more selective surveillance
for nontuberculous mycobacteria, as opposed to the minimum
quarterly surveillance for many other respiratory pathogens
(14).
Our anecdotal evidence suggested that RGM could be re-
covered from Burkholderia cepacia selective agar (BCSA), one
of the culture media utilized in routine cultures of respiratory
secretions from CF patients. Furthermore, recovery was found
to be enhanced if the incubation period for BCSA was ex-
tended from the standard 5 days to 14 days. To assess the
potential impact of extending the incubation of respiratory
secretions from CF patients in BCSA cultures, we imple-
mented this change and examined results from all routine and
AFB culture results for CF patients for the period 2 years
before and after this modification.
MATERIALS AND METHODS
Culture methods. Routine cultures for pathogens from CF patients and AFB
cultures and smears were performed using standardized methods (6), except that
the incubation period for BCSA was extended from 5 to 14 days in September
2007. The plates were incubated at 35°C for the initial 5 days and then at 30°C
for the remainder of the 14 days, with additional plate reading at a minimum of
7, 10, and 14 days. Suspicious colonies were stained using Kinyoun stain, and
acid-fast organisms were identified using 16S rRNA sequencing. The species of
isolates classified as belonging to the M. chelonae/M. abscessus complex were
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determined using hsp65 sequencing. Because some strains of M. abscessus and M.
massiliense share the same 16S rRNA and hsp65 sequences, for the purposes of
this study, both species were classified as M. abscessus (3).
Patient records. Culture results for patients with CF were abstracted from a
database maintained by the Clinical Microbiology-Immunology Laboratories at
the University of North Carolina Hospitals for the period from September 2005
through August 2007 (before) and the period from September 2007 through
August 2009 (after). Data were obtained from all patients diagnosed with CF,
and a subset of regularly followed patients was identified as those for whom at
least one sample was cultured in each of the 4 years of the study. Infection with
RGM was defined on the basis of American Thoracic Society microbiological
criteria (7) as two or more samples culture positive for RGM during either 2-year
study period. This study was approved by the Institutional Review Board at the
University of North Carolina at Chapel Hill.
Statistical analysis. Data are presented as means and standard deviations
(SDs) for continuous variables and proportions for categorical variables. Gen-
eralized estimating equations (GEEs) with a compound symmetric covariance
structure were used to compare recovery rates across time for the AFB and
routine tests in the before and after periods. A bootstrap of the kappa coefficient
conducted by sampling patient identification codes was used to assess the inde-
pendence of the AFB test and the routine test during the after period, as well as
the strength of their agreement. To estimate the relative sensitivity of the AFB
and routine tests, a null-model GEE with log link and compound symmetric
covariance, along with the assumption that the false-positive rate was very low,
was used to obtain a point estimate and 95% confidence interval for the ratio of
the sensitivity of the AFB test to that of the modified routine test. Statistical
significance for all analyses was established at 0.05. All analyses were conducted
in GraphPad Prism (La Jolla, CA), R, or SAS, version 9.2 (SAS, Cary, NC),
software.
RESULTS
Recovery of RGM from all CF patients. We examined mi-
crobiological culture data from all CF patients followed at our
institution for the 2 years before and after a change in meth-
odology designed to enhance recovery of RGM from routine
cultures. A total of 4,212 samples for routine cultures and
1,810 samples for AFB culture from 670 patients were avail-
able for analysis in the before period, and 4,720 samples for
routine culture and 2,179 samples for AFB culture from 695
patients were available in the after period (Table 1). The
change in culture methodology increased the total number and
proportion of routine cultures from which RGM were recov-
ered, from 31 (0.7%) in the before period to 133 (2.8%) in the
after period (P  0.001). In contrast, there was no significant
change in the proportion of AFB cultures from which RGM
were recovered (5.5% before, 5.7% after; P  0.93) (Table 1).
Interestingly, the numbers of samples for both routine and
AFB cultures obtained per patient were higher in the after
period than in the before period.
Recovery of RGM from routine and AFB cultures. To esti-
mate the rates of recovery of RGM from routine and AFB
cultures, we examined the subset of cultures from the after
period in which both routine and AFB cultures were per-
formed with the same respiratory sample (defined as a sample
collected from the same patient on the same date, n  2,109).
We observed that 139 (6.6%) of these respiratory samples were
RGM positive, defined as having RGM recovered from either
routine culture or AFB culture (or both). Of these 139 RGM-
positive respiratory samples, RGM were recovered less fre-
quently from routine cultures (92/139, 66%) than from AFB
cultures (114/139, 82%); 48% (67/139) of the samples were
positive by both routine and AFB cultures. The estimate for
the kappa test of agreement was 0.62 (95% confidence inter-
val  0.49 to 0.75, P  0.001), suggesting moderate to sub-
stantial agreement between the two tests. To examine whether
RGM organism burden influenced detection rates, we identi-
fied the subset of RGM-positive respiratory samples for which
the stain for AFB was also positive (78 of the 139 RGM-
positive samples, 56%), since staining positive for AFB may
reflect a larger quantity of organisms. For these 78 respiratory
samples, detection sensitivity in routine culture remained sim-
ilar (53/78, 68%), whereas the rate of detection in AFB cul-
tures was higher (75/78, 96%).
To determine whether other pathogens present in the respi-
ratory sample impacted recovery of RGM from routine or
AFB cultures, we examined the influence of Staphylococcus
aureus, Pseudomonas aeruginosa, nonpseudomonal, nonfer-
menting Gram-negative rods (Stenotrophomonas, Achromo-
bacter, or Burkholderia species), and mold on recovery of RGM
from routine or AFB cultures. Using a generalized estimating
equation model, we found that the presence of nonpseu-
domonal Gram-negative rods and/or mold decreased the prob-
ability of recovery of RGM from routine cultures relative to
that from AFB cultures (odds ratio, 0.68; P  0.05). Of note,
both nonpseudomonal Gram-negative rods and mold were ob-
served to be capable of growth on BCSA and were found
growing on BCSA plates for which BCSA cultures were neg-
ative for RGM but AFB cultures were positive.
RGM recovery in regularly followed patients. The clinical
impact of changing the culture methodology was assessed with
a subset of 340 CF patients followed regularly, defined as
having at least one sample cultured during each of the 4 years
of the study. From these patients, 3,154 samples for routine
culture and 1,199 samples for AFB culture were obtained in
the before period, and 3,381 samples for routine culture and
1,545 samples for AFB culture were obtained in the after
period. Consistent with the previous findings, the change in
culture methodology significantly increased the number of rou-
tine cultures from which RGM were recovered in the regularly
followed patients from 25 (3.2%) to 111 (8.2%, P  0.001). In
the after period, 28 regularly followed patients had at least one
sample from which RGM was recovered by routine culture,
and 16 met microbiological criteria for RGM infection on the
basis of the routine culture results alone. Both of these num-
bers were significantly higher than those in the before period
(Table 2) and were similar to the results from AFB cultures: 22




No. of patients 670 695
Routine culture
Total no. of samples 4,212 4,719
Avg no. of samples cultured
per patient annually
2.4  2.9 2.7  3 0.01
No. (%) RGM-positive
samples cultured
31 (0.7) 133 (2.8) 0.001
Culture for AFB
Total no. of samples 1,810 2,179
Avg no. of samples cultured
for AFB per patient
annually
1.0  1.9 1.2  2 0.01
No. (%) of RGM-positive
samples cultured
99 (5.5) 125 (5.7) 0.93
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individual patients had at least one sample RGM positive by
AFB culture in the after period, and 16 patients met the mi-
crobiological criteria for RGM infection on the basis of AFB
culture results alone. Of note, the results from AFB cultures
were similar in the before and after periods (Table 2).
A total of 20 patients in the after period were identified as
having RGM infection by routine culture, AFB culture, or
both. Twelve of these patients (Table 3, patients 1 to 12) were
identified as having RGM infection from both the routine and
AFB culture results. Four patients (Table 3, patients 13 to 16)
were identified as having RGM infection from the routine
culture results but not the AFB culture results. At least three
samples from each of these four patients were cultured for
AFB during the after period, and for two of the four patients,
a single sample was RGM positive by AFB culture but they did
not meet the definition of infection. An additional four pa-
tients (Table 3, patients 17 to 20) had RGM infection identi-
fied by AFB cultures but not by routine cultures. Between 3
and 15 samples from these four patients underwent routine
cultures in the after period, and three of the four had one
RGM-positive routine culture result. Interestingly, of the four
patients in whom RGM infection was identified by AFB cul-
ture but not routine culture, three were colonized with
nonpseudomonal Gram-negative rods. Among all 20 patients
with RGM infection, only 3 patients had infection with RGM
identified by one culture method but no RGM-positive cul-
tures by the other. Each of these patients had a total of only
two or three samples RGM positive by culture, suggesting a
relatively modest burden of infection.
Estimated sensitivity of RGM recovery from regularly fol-
lowed CF patients. To expand upon our earlier estimates of
RGM detection sensitivity, we examined all cultures of sam-
ples from regularly followed patients in the after period to
assess the relationship between the percentage of cultures pos-
itive for RGM and the total number of RGM-positive cultures.
We reasoned that patients with a large total number of samples
positive by culture likely had persistent infection and that the




No. of patients 340 340
Routine cultures 3,154 3,381
Total no. of samples 4.6  2.6 5.0  2.8 0.01
Avg no. of samples cultured
per patient annually
No. (%) of RGM-positive
samples
25 (3.2) 111 (8.2) 0.001
No. (%) of patients with
any RGM
11 (3.2) 28 (8.2) 0.01
No. (%) of patients with
RGM infectiona
5 (1.5) 16 (4.7) 0.024
Cultures for AFB
Total no. of samples 1,199 1,545
Avg no. of samples cultured
per patient annually
1.8  2.1 2.3  2.5 0.001
No. (%) of RGM-positive
samples
80 (6.7) 102 (6.6) 0.81
No. (%) of patients with
any RGM
19 (5.6) 22 (6.5) 0.75
No. (%) of patients with
RGM infection
14 (4.1) 16 (4.7) 0.85
a RGM infection was defined as two or more RGM-positive cultures for an
individual patient within a 2-year study period (before or after).
TABLE 3. All patients meeting criteria for RGM infection by either AFB culture, routine culture, or both in the after period
Culture meeting infection criteria Patientno.
No. (%) of patients
% nonpseud GNRb
routine cultures





Both AFB and routine cultures 1 22 4 (18) 20 3 (15) 91
2 8 2 (25) 8 2 (25) 25
3 11 3 (27) 7 6 (86) 0
4 9 3 (33) 7 5 (71) 67
5 16 6 (38) 6 4 (67) 19
6 22 11 (50) 15 11 (73) 50
7 7 4 (57) 6 5 (83) 100
8 16 10 (63) 15 9 (60) 0
9 12 9 (75) 11 10 (91) 83
10 14 11 (79) 7 4 (57) 0
11 14 12 (86) 12 12 (100) 0
12 9 9 (100) 10 10 (100) 0
Routine cultures only 13 9 4 (44) 4 1 (25) 0
14 7 3 (43) 3 0 (0) 14
15 13 6 (46) 3 1 (33) 92
16 13 2 (15) 3 0 (0) 15
AFB cultures only 17 15 1 (7) 13 2 (15) 87
18 8 1 (13) 3 2 (67) 88
19 3 0 (0) 3 2 (67) 0
20 13 1 (8) 13 12 (92) 100
a RGM, RGM positive.
b Nonpseud GNR, nonpseudomonal Gram-negative rod (Stenotrophomonas, Achromobacter, or Burkholderia species) positive.
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fraction of cultures in which RGM were actually recovered for
these patients would serve as an estimate of the detection
sensitivity. Among the patients with the highest number of
positive cultures (9 or more), rates of recovery of RGM were
75.3% for routine cultures and 83.0% for AFB cultures. These
values are consistent with a plateau observed with nonlinear
curve fitting of the entire data set (Fig. 1). A GEE model
comparing the sensitivity of AFB culture to that of the modi-
fied routine culture for recovery of RGM yielded a ratio esti-
mate of 1.50, consistent with a higher sensitivity of the AFB
culture method, although the 95% confidence interval was
wide (0.94, 2.42) and the possibility of equivalence could not be
rejected.
DISCUSSION
A relatively simple change to the culture methodology sig-
nificantly enhanced recovery of RGM from routine cultures of
samples from CF patients, resulting in an 4-fold increase in
the number of RGM-positive routine cultures. Detection sen-
sitivities estimated by both culture-based (percent detection
from all samples from which RGM were recovered) and pa-
tient-based (percent detection from samples from patients with
clear evidence of persistent infection) methods yielded com-
parable results, suggesting a sensitivity for routine cultures of
65 to 75%. While it is lower than the estimated 80 to 85%
sensitivity for AFB cultures in this study (which is consistent
with previously reported values [5]), the reduced sensitivity was
offset by the fact that samples for routine culture were ob-
tained more than twice as often as samples for AFB culture for
this cohort of CF patients.
In practice, both methods performed similarly for identifi-
cation of RGM infection within a clinical population of regu-
larly followed CF patients. In fact, the modified routine culture
method resulted in identification of several patients with RGM
infection that were not identified through AFB culture alone,
although this method also failed to identify some patients. The
group of patients that were not identified to have infection with
RGM by one or the other method generally appeared to have
a relatively modest burden of infection, and the failure of one
method relative to the other may have reflected random
chance. The discrepancies between culture methods highlight
the fact that neither is 100% sensitive for detection of RGM in
respiratory secretions.
Overall, these data suggest that application of the change in
methodology for all routine cultures would improve identifi-
cation of CF patients with RGM infection. The growing evi-
dence that chronic RGM infection is associated with worse
clinical outcomes (4, 10, 11) suggests that this change could
convey clinical benefit, and improved screening would also be
important, given the increasing use of chronic azithromycin
therapy, for which infection with environmental mycobacteria
is a contraindication (13). However, it is important to note that
the total number of newly identified patients was relatively
small and the burden of infection was relatively low, and de-
finitively proving the clinical benefit of improved identification
by this or any method would be exceedingly difficult without
prolonged study of a large population of patients with CF.
We recognize that potential benefits of improved screening
for RGM could likely be achieved through more frequent use
of AFB cultures. However, such a change would entail addi-
tional cost that might be difficult to justify without strong
evidence of clinical benefit. In contrast, the modest additional
effort to detect RGM on routine culture, including an addi-
tional reading of plates at 7, 10, and 14 days of incubation, is
significantly less than that required for a separate AFB culture.
Indeed, reducing the cost of monitoring for RGM infection
could be another rationale for using the modified routine cul-
ture methodology in lieu of AFB cultures for selected patients
to follow RGM infection.
While it is beneficial, the modified routine culture method-
ology does have limitations. This methodology would not elim-
inate the need for screening AFB cultures, which would still be
necessary to detect other environmental mycobacterial species,
such as M. avium complex, that cannot be recovered from
BCSA or other media utilized for routine culture of samples
from CF patients. Furthermore, our data suggested that the
routine culture method for detection of RGM must be utilized
cautiously with patients infected with mold or nonpseu-
domonal Gram-negative rods, such as Burkholderia or
Stenotrophomonas species. These pathogens are capable of
growth on BCSA agar and may outcompete RGM when they
are present in the respiratory sample. The negative relation-
ship between recovery of RGM from routine culture and re-
covery of nonpseudomonal, nonfermenting Gram-negative
rods or mold is a concern, since these pathogens have been
recovered more frequently from patients with environmental
myocbacterial infection in previous studies (4, 9).
In summary, we report a simple change in culture method-
ology that allows recovery of RGM from routine cultures of
respiratory specimens from CF patients. Adoption of this
method, either universally or for selected patients, could im-
prove detection and management of RGM infections in pa-
tients with CF.
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